Diabetes healthcare is being boosted by greater access to and understanding of what these little bits of wearable wellness can do for users. When we published a feature, A Sensor Adventure, in the summer of 2017, there really weren’t that many about, they read more »

The Eversense system continually measures interstitial fluid glucose levels in adults with diabetes for the operating life of the sensor, which is 180 days (six months). Although the CGM is implanted the user wears a reader on the skin, which delivers glucose trend read more »

Roche’s Accu-Chek brand is bringing Senseonic’s Eversense CGM to the UK and other countries in Europe shortly, having gained CE clearance last week (14 September 2017). A recent survey of 17,317 Type 1 diabetes (T1D) individuals in the American-based T1D Exchange registry reported read more »